pharmacovigilance

Documents about pharmacovigilance

• Active Pharmacovigilance of Anti-cancer Medicines#1382207ClinicalTrials.gov
• Cohort Event Monitoring in Sub Saharan Africa#1261604ClinicalTrials.gov
• COMPARATIVE ANALYSIS OF THE EUROPEAN UNION'S PHARMACOVIGILANCE FRAMEWORK WITH INDIA'S DRUG SAFETY REGULATIONS#1527712Zenodo (CERN)
• The WHO-ISoP Pharmacovigilance Curriculum: 2026 Update#1020730Springer Nature OA
• Guidance on the interpretation of pharmacovigilance signal detection data and analyses#1537649HAL (France)
• Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)#916246ClinicalTrials.gov
• Pharmacovigilance Data From Digital Health Systems: Regulations, Implications, and Opportunities—A TransCelerate Perspective#153887Springer Nature OA
• Effect of Deuterated Drugs on Safety: Insights from Pharmacovigilance Data Analysis#1081235OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Adverse Drug Reactions in Pediatrics: Experience of a Regional Pharmacovigilance Center#842447ClinicalTrials.gov
• Pharmacovigilance in medical cannabis therapy among physicians in Poland: pharmacovigilance knowledge, ADR reporting practice and cannabis-related safety reporting.#1091019NCBI PubMed Central
• The EUROmediCAT Network and Databases: A Resource for Pharmacovigilance in Pregnancy#231766HAL (France)
• The Real-World Safety Profile of Haloperidol: A Comprehensive Pharmacovigilance Analysis Using the Large-Scale FAERS Database#1414860Europe PMC
• Cannabinoids and Adverse Convulsive Effects: A Pharmacovigilance and Addictovigilance Analysis of Cases Reported in France#147543HAL (France)
• JAK Inhibitors and Memory Impairment: Disproportionality Analyses in the WHO Global Pharmacovigilance Database, VigiBase#274118HAL (France)
• Critical Appraisal of Artificial Intelligence for Rare-Event Recognition: Principles and Pharmacovigilance Case Studies#299168Springer Nature OA
• Interferon α 2b Pharmacovigilance Study#862075ClinicalTrials.gov
• Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group#172254Springer Nature OA
• Analysis of interstitial lung disease in pharmacovigilance databases: Coding challenges and interpretation biases - An update#178083HAL (France)
• Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database#223135OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Anti-TNF-induced vasculitis: analysis of data from the French national pharmacovigilance database#1434297HAL (France)
• Assessing safety trends of withdrawn medications: A data-driven pharmacovigilance approach using growth models#5267Europe PMC
• Electronic Study for Anastrozole Pharmacovigilance Evaluation#1185568ClinicalTrials.gov
• The WHO-ISoP Pharmacovigilance Curriculum: 2026 Update#1367163HAL (France)
• High-throughput signal detection of hepatotoxic drug-drug interactions in hospitalized elderly patients: an NLP-driven pharmacovigilance study.#295606PubMed
• Is There a ‘Best’ Way for Patients to Participate in Pharmacovigilance?#113359PhilArchive
• Governing AI for Pharmacovigilance in Low-Income Countries: Systems Perspective.#1134700NCBI PubMed Central
• Development of Cynomolgus Monkey#1180141Springer Nature OA
• Severe Cutaneous Adverse Reactions Associated With Newer-Generation Antiseizure Medications: A Real-World Pharmacovigilance Study Based on FAERS and JADER#266507Europe PMC
• Pengaruh Vaksin Sinovac terhadap Siklus Menstruasi pada Remaja Perempuan Berbasis Studi Farmakovigilans di Banjarmasin Selatan: Effect of Sinovac Vaccine on Menstrual Cycle in Adolescent Girls Based on Pharmacovigilance Study in South Banjarmasin#1003960Jurnal Surya Medika (JSM)
• Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review#226830HAL (France)
• Towards Post-Quantum Secure Pharmacovigilance with ML-KEM and ML-DSA#267558arXiv CS
• A FAERS pharmacovigilance analysis of dementia-related adverse event reports.#1415649NCBI PubMed Central
• Supplementary file 1_Immune checkpoint inhibitor-related myotoxicity in lung cancer: a decade-long real-world pharmacovigilance analysis of the FAERS database.docx#1038752Figshare
• Impact of the vaccination against SARS-CoV-2 campaign on disproportionality indicator from the WHO pharmacovigilance database: A competition bias study from case/non-case analysis#676855HAL (France)
• Vaccines and the risk of Guillain-Barré syndrome: A French pharmacovigilance analysis#126876HAL (France)
• Ecopharmacovigilance and pharmacovigilance: an analysis of environment-related reporting in VigiBase.#145918NCBI PubMed Central
• A pharmacovigilance study of sirolimus-associated adverse events in organ transplantation.#295231NCBI PubMed Central
• AI for Causality Assessment in Pharmacovigilance: Protocol for a Scoping Review.#421023NCBI PubMed Central
• Guillain–Barré syndrome associated with immune checkpoint inhibitors exposure: a pharmacovigilance study#676798HAL (France)
• Reproductive System Pathology of Cynomolgus Monkey#1180142Springer Nature OA
• Clostridioides Difficile#1428418Springer Nature OA
• Rotavirus Vaccines#1428421Springer Nature OA
• Pneumococcal Vaccines#1428424Springer Nature OA
• Tuberculosis Vaccines#1428426Springer Nature OA
• The EUROmediCAT Network and Databases: A Resource for Pharmacovigilance in Pregnancy.#148525NCBI PubMed Central
• A Feasibility Study of Drug–Drug Interaction Signal Detection in Regular Pharmacovigilance#219319Ora Oxford University Research
• CFTR modulators-induced acne: Case series and analysis of pharmacovigilance databases#253987HAL (France)
• A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting#325330ClinicalTrials.gov
• Evaluation of a simplified pharmacovigilance tool for general practitioners: 5 years of insight#676801HAL (France)
• Introduction to the Species of Cynomolgus Monkey#1180140Springer Nature OA